ArticleHaematologica2025
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Deep learning differentiates myeloproliferative neoplasms and predicts JAK2 and CALR mutations from bone marrow smears.Annals of hematology · 2026Article
- Artificial intelligence in small tissue biopsies: diagnostic applications, histochemical integration, and methodological challenges in surgical pathology.Histochemistry and cell biology · 2026Review
- Molecular Pathology, Artificial Intelligence, and New Technologies in Hematologic Diagnostics: Translational Opportunities and Practical Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Robotics-assisted automated staining of bone marrow biopsies: addressing the inconsistency in histological diagnosis of hairy cell leukemia variants.Annals of medicine and surgery (2012) · 2026Article
- Advancements in bone marrow biopsy: the role of omics and artificial intelligence in hematologic diagnostics.Frontiers in medicine · 2026Review
- Precision medicine in myelofibrosis: from molecular profiling to personalized therapy.Frontiers in oncology · 2026Review
- A Dual-Feature Framework for Enhanced Diagnosis of Myeloproliferative Neoplasm Subtypes Using Artificial Intelligence.Bioengineering (Basel, Switzerland) · 2025Article
- Predicting modelling for early diagnosis in early myeloproliferative neoplasms, not otherwise specified. Evidence from a machine learning study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evaluation of bone marrow pathology is essential for diagnosing and classifying myeloproliferative neoplasms (MPN). However, morphological assessments of bone marrow trephine (BMT) sections by hematopathologists are inherently subjective; thus, an accurate and objective diagnostic system is needed. Based on U2-Net, UNeXt, and ResNet, we developed an automated quantitative analysis platform for BMT sections from MPN patients and non-neoplastic cases (N=342 total) to enhance the accuracy of diagnosis and classification of MPN. Bone marrow metrics, including marrow cellularity, the myeloid-to-erythroid ratio, megakaryocyte morphology and distribution, and the grading of marrow fibrosis, were quantitatively analyzed (with an accuracy of approximately 0.9) based on the accuracy segmentation and identification of various cells and tissues (with an intersection over union of roughly 0.8). A bone marrow classification model incorporating bone marrow metrics, a clinical classification model utilizing clinical features, and a comprehensive classification model that includes both bone marrow metrics and clinical features were developed using random forest classifiers to differentiate MPN subtypes and non-neoplastic conditions. The bone marrow and comprehensive classification models reached a macro- average area under the curve (AUC) of 0.96 for differentiating MPN subtypes and non-neoplastic cases. The clinical classification model attained a macro-average AUC of 0.92. This platform is highly accurate for quantitatively analyzing bone marrow pathology and classifying MPN subtypes and non-neoplastic cases. It can be a potentially auxiliary diagnostic tool for hematopathologists when dealing with patients with suspected MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.